Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A growing movement of patients, doctors, and researchers is challenging whether FDA-approved cancer drug doses are actually optimal. Evidence from multiple countries suggests lower doses of immunotherapy drugs like nivolumab and pembrolizumab may work just as well with fewer side effects and lower costs — but financial incentives keep the status quo in place.
A quiet but determined movement is challenging one of oncology's biggest assumptions: that FDA-approved cancer drug doses are the right ones. Patients, researchers, and clinicians across the US, Europe, and India are building a case that lower doses of popular immunotherapy drugs — like nivolumab (Opdivo) and pembrolizumab (Keytruda) — may deliver similar survival benefits with significantly fewer toxic side effects and at a fraction of the cost.
The financial stakes are enormous. Merck earned nearly $32 billion from pembrolizumab alone in one year, and a study of 29 expensive cancer drugs estimated that using minimum necessary doses in 2024 could have saved the US healthcare system roughly $31 billion. Yet dose-optimization trials remain rare, largely because pharmaceutical companies, hospitals, and even insurers have financial incentives tied to higher-dose prescriptions — including a Medicare add-on payment of 6% of a drug's average price per infusion. The FDA's Project Optimus, launched in 2021, is pushing for better dose-ranging studies before new drug approvals, and has already led to lower-dose approvals for four lung cancer drugs. But for drugs already on the market, the agency has limited power to compel new dosing studies.
By the Numbers:
Why it matters: For patients already burdened by severe side effects and crushing drug costs, the question of optimal dosing isn't academic — it's life-altering. Until financial incentives align with patient-centered outcomes, the push for dose optimization will remain an uphill battle.
